Genetic loss of function studies in murine tumor models have been essential in the analysis of downstream mediators of oncogenic transformation. Unfortunately, these studies are frequently limited by the availability of genetically modified mouse strains. Here we describe a versatile method allowing the efficient expression of an oncogene and simultaneous knockdown of targets of interest (TOI) from a single retroviral vector. Both oncogene and TOI specific miR30-based shRNA are under the control of the strong viral LTR promoter, resulting in a single shared RNA transcript. Using this vector in a murine syngeneic bone marrow transplantation model for BCR-ABL induced chronic myeloid leukemia we find that oncogene expression and target knockdown in primary hematopoietic cells with this vector is efficient both in vitro and in vivo, and demonstrate that Raf1, but not BRAF, modulates BCR-ABL dependent ERK activation and transformation of hematopoietic cells. This expression system could facilitate genetic loss-of-function studies and allow the rapid validation of potential drug targets in a broad range of oncogene driven murine tumor models.
Introduction
Malignant cells frequently have rewired signaling networks required for growth and survival.
Identification of essential nodes within these oncogene mediated signaling networks will be crucial for the development of novel anticancer therapies. In vivo tumor models [1] [2] [3] have been vital for the identification of signaling pathways underlying malignant transformation, an important aspect in the validation of potential therapeutic targets. A powerful approach to pin down essential components of oncogenic signaling cascades in vivo has been the use of murine bone marrow transplantation (BMT) models in combination with knock-out bone marrow cells [4] [5] [6] [7] [8] [9] [10] . However, using knock-out mice to define critical signaling cascades or potential drug targets can be time-consuming and may in some cases be impossible. Some knock-out mice have severe defects leading to embryonic lethality, others
may not yet be available or have to be crossed back to a syngeneic background to prevent graft rejection, limiting efficiency and utility of this approach.
The discovery of RNA interference introduced a new approach to inactivating genes in live cells.
Subsequently, the development of vector-expressed hairpin-siRNAs (shRNA) paved the way for prolonged, stable knockdown of genes 11 . For in vivo application of siRNA mediated gene suppression, shRNAs have been accommodated for the expression from retroviral and lentiviral vectors 12 . The improvements in shRNA delivery systems have made gene inactivation by RNAi a rapid, versatile and efficient approach to study gene function 13, 14 . The combination of retroviral hairpin siRNA delivery and retroviral infection/transplantation models in mice should alleviate the inherent problems of transgenic/knock-out mice such as lack of suitable genetically modified mice due to embryonic lethality, time consuming breeding or back crossing and limited availability. Furthermore, a functional incomplete siRNA mediated knockdown may mimic target inhibition by a potential drug more closely than a knock-out, where gene function is completely abolished. However, expression of the oncogene and the target of interest (TOI)-specific shRNA from two different vectors may lead to uncoupling of expression and escape of oncogene transformed cells e.g. by silencing of the shRNA or by outgrowth of single-infected cells.
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Here we describe a reliable, highly versatile retroviral single vector system in which a potent and durable knockdown of variable TOIs by miR30-based shRNAs can be combined with efficient expression of a desired oncogene or other transgene. Directly coupling oncogene expression with TOI knockdown was achieved by cloning an oncogene directly downstream of a miR30-based shRNA (miR TOI ) under control of the MSCV retroviral LTR polymerase (Pol) II promoter, resulting in one shared RNA transcript. By coupling expression of the shRNA to the driving oncogene, we minimize the chances for escape and ensure stable and durable TOI knockdown in every transformed cell.
To validate our vector system, we turned to a well-established murine retroviral syngeneic BMT model of BCR-ABL induced myeloproliferative neoplasm 2, 15 to investigate the role of Raf1 and BRAF in BCR-ABL mediated leukemogenesis. Raf kinases are key enzymes to activate the MAPK/ERK cascade 16 , one of the central pathways activated by BCR-ABL 17 . Using our coupled expression system, we here show that Raf1 but not BRAF modulates the BCR-ABL mediated induction of a CML-like disease in mice.
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Methods
Growth factors and antibodies
Recombinant murine interleukin-3 (mIL-3), interleukin-6 (mIL-6) and stem cell factor (mSCF) were purchased from R&D Systems (Minneapolis, MN, USA). BCR-ABL and Abl was detected by immunoblotting using an Abl-specific antibody 8E9 (BD Biosciences, San Jose, CA, USA), β-actin antibody was from Sigma-Aldrich (AC-15, St. Louis, CA, USA). Tyrosine phosphorylation was detected using a mixture of monoclonal anti-phosphotyrosine antibody 4G10 (Millipore, Billerica, MA, USA) and PY20 (BD Biosciences, San Jose, CA, USA). Raf1 (C-12), BRAF (H-145) and STAT5 A/B (C-17) antibodies came from Santa Cruz Biotechnology (Santa Cruz, CA, USA), p53 antibody came from NovoCastra (CM5, NovoCastra, Newcastle upon Tyne, U.K.). Antibodies detecting phosphorylated AKT (Ser-473), phosphorylated ERK1/ERK2, pan-AKT and pan-ERK1/ERK2 were purchased at Cell Signaling Technology (Danvers, MA, USA). Monoclonal phosphospecific STAT5 A/B antibody was a generous gift from Tom Wheeler (Hamilton, New Zealand).
Plasmids
PLMPmiR
Ctrl was generated by subcloning the target specific hairpin sequence from pSM2c (Catalog number RHS1707 Non-silencing shRNA vector for Ctrl miR; Openbiosystems upon BioCat, Heidelberg, Germany) to pLMP (Openbiosystems) according to manufacturer's instructions. 21 mer sequences for miR were calculated using the RNAi Central algorithm, miR For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
In vivo leukemogenesis studies
Quantitative PCR
RNA from cell lines and tissues was isolated with RNeasy Mini Kit (Qiagen, Hilden, Germany).
cDNA was generated using Titan One Tube RT-PCR Kit (Roche Applied Science, Mannheim, Germany). qRT-PCR was performed using Platinum SYBR Green qPCR SuperMIX UDG (Invitrogen) using primers specific for murine GAPDH (fw: GGTCATCCCAGAGCTGAACGG, rev: CCTGCTTCACCACCTTCTTG) and murine Raf1 (fw1: TCTGAAGGTGAGAGGCCT, rev1: GGC-ATCGGTGTTCCAATCT, fw2: GTGATGCTGTCTACTCGGA, rev2: GGTCAACCACCTTTA-GGATC). SD was calculated as described by Livak et al. 19 .
Results
An alternative strategy to achieve simultaneous expression of cDNAs and shRNAs in individual cells
While it is possible to simultaneously overexpress an oncogene and downregulate a TOI by double infection of cells with two retro-or lentiviral constructs, one encoding the oncogene, the other encoding for a TOI specific shRNA (shRNA Figure 2C ).
In addition, we also cloned a p53 specific miR30-based shRNA (miR p53 ) in the BCR-ABL encoding pMmiR TOI -oncogene vector and showed functionality of the miR p53 in both vectors ( Figure 2D and E).
12 p53 knockdown previously has been shown to lead to an acceleration of BCR-ABL induced leukemogenesis in mice 29 and thus could serve as a positive readout control in further experiments. In summary, these data demonstrate that miR TOI expressed together with the BCR-ABL oncogene on one single mRNA transcript driven by the LTR Pol II promoter leads both to effective TOI knockdown and expression of the oncogene.
Next we examined the effects of simultaneous Raf1 knockdown and BCR-ABL expression on ERK activation in two hematopoietic cytokine dependent cell lines. We infected 32D cells (IL-3 dependent murine myeloid cell line, Figure 2F ) and Ba/F3 (IL-3 dependent murine pro B-cell line, Figure 2G) with pMmiR Raf1 -BCR-ABL or pMmiR Western blot analysis showed sustained BCR-ABL expression and strong Raf1 knockdown (more than 90%) over a period of more than 4 weeks both in vitro and in vivo ( Figure 3A) . Interestingly, miR Figure 3B ) nor its activation was elevated ( Figure 3C ).
Alternatively secreted or circulating cytokines might reactivate ERK independent of BCR-ABL signaling. IL-3 for example is able to activate ERK in the absence of Raf1 (Figure 2F and G) . Figure 5B ) and lower peripheral leukocyte counts ( Figure 5C ). These results were verified using a second independent miR Raf1 ( Figure 2B (indicated by **) and Supplementary Figure   S8 ).
Effects of
As expected, p53 knockdown in this system slightly although non-significantly accelerated the progression of leukemia in this highly aggressive CML model ( Figure 5D ) 29 . Sustained and efficient 
BRAF is dispensable for BCR-ABL-dependent transformation
Two papers suggested an involvement of BRAF in BCR-ABL mediated transformation by overexpressing or deleting the BRAF inhibitor SPA-1 31, 32 . As BRAF knock-out mice are embryonic lethal 33 studies utilizing BRAF knock-out bone marrow have not been performed. Here we analyzed the function of BRAF in comparison to Raf1 for BCR-ABL mediated transformation using our vector system. Interestingly, in contrast to Raf1, BRAF knockdown had no impact on BCR-ABL dependent activation of ERK in vitro ( Figure 6A ). Also, BRAF depletion in primary murine bone marrow cells did not alter colony-forming numbers and shape in a methylcellulose assay, suggesting that BRAF is dispensable for BCR-ABL mediated transformation in this assay ( Figure 6B ). We finally also investigated the role of BRAF for BCR-ABL mediated leukemogenesis in the previously described murine CML model (for summary of all transplants see Table 1 ). Neither knockdown of Raf1 nor of BRAF had an influence on the phenotype of the disease (Supplementary Figure 4) . However, in contrast to Raf1, BRAF knockdown did not affect BCR-ABL dependent leukocytosis, leukemic burden in the peripheral blood ( Figure 6D and E) or overall survival despite very efficient BRAF knockdown ( Figures 6C and 6F ). 
